Cancer patients in Greater Manchester test cutting-edge wearable technology to keep doctors in the loop
- The trial will ‘shape the future of cancer care in the UK’
- Smart watches and rings will monitor patients during their treatment
- 38% of cancer cases are ‘preventable’
Health sensors which track vital signs are allowing doctors to assess the progress of their patients.
The trail, called EMBRaCE, (Enhanced Monitoring for Better Recovery and Cancer Experience) uses statistics from smart devices to give doctors key insight.
The wearable technology will trach the patients heart rate, temperature, physical activity and sleep.
The EMBRaCE trail is a collaboration between Manchester University NHS Foundation Trust, The Christie NHS Foundation Trust, Zenzium and The University of Manchester.
Dr Anthony Wilson, consultant in anaesthesia and critical care at Manchester Royal Infirmary (MRI) is the clinical lead for the project.
The new ground-breaking EMBRaCE trial in Greater Manchester is testing cutting-edge wearable technologies involving patients who have received cancer treatment.
Find out more https://t.co/uQHYDpRFq8 pic.twitter.com/JRP14XnHq1— MFT Research and Innovation (@MFT_Research) January 26, 2022
He said: “Cancer places a huge burden on the lives of people everywhere. This study uses cutting-edge technology that can monitor people during their treatment, with devices that they can wear all the time.
We hope that it will provide new insights into how people cope with cancer treatment and what we can do to improve their recovery
Adam Conroy, health development co-ordinator for Moss Side, shared locals’ cancer worries from last month’s health partnership meeting, which focused on cancer awareness.
Adam said cancer cases were “38% preventable” and that “fear” was the most common feeling among participants.
Anthony Bashall, managing director of Zenzium, understands patients’ anxieties and said: “The EMBRaCE programme addresses these challenges head on, allowing participants to take more proactive control of their cancer journey through wearables and the data they provide clinicians.
These patient pioneers will help shape the future of cancer care in the UK
Professor Dave Shackley, director of Greater Manchester Cancer Alliance and the senior responsible officer for cancer in Greater Manchester, said: “We are delighted in Greater Manchester to have such a fantastic study taking place.
“The smart use of digital technology is going to be pivotal for high quality, personalised cancer care for our patients.”